Compare SNFCA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNFCA | CADL |
|---|---|---|
| Founded | 1965 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 357.4M |
| IPO Year | 1995 | 2021 |
| Metric | SNFCA | CADL |
|---|---|---|
| Price | $9.68 | $5.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 35.5K | ★ 1.2M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.51 | ★ 58.62 |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $344,587,538.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.57 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $7.70 | $4.25 |
| 52 Week High | $11.00 | $7.24 |
| Indicator | SNFCA | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 50.33 |
| Support Level | $8.45 | $4.58 |
| Resistance Level | $9.76 | $5.42 |
| Average True Range (ATR) | 0.30 | 0.24 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 84.22 | 75.63 |
Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.